BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...Haul” ). Three of the four -- Annexon Inc. (NASDAQ:ANNX), Nurix Therapeutics Inc. (NASDAQ:NRIX) and iTeos Therapeutics...
...ENPP1 - Ectonucleotide pyrophosphatase/phosphodiesterase 1 Paul Bonanos, Associate Editor Annexon Inc. iTeos Therapeutics S.A. Nurix Therapeutics Inc. Inozyme Pharma Inc. 4D Molecular Therapeutics Inc. AlloVir iTeos Therapeutics...
BioCentury | Jul 21, 2020
Finance

As trio of companies enter IPO queue, four more propose terms

...Several more companies in the queue proposed terms for their listings, including Annexon Inc., iTeos Therapeutics...
...Inc. and Inozyme Pharma Inc. Paul Bonanos, Associate Editor Everest Medicines Ltd. Freeline Therapeutics Ltd. Checkmate Pharmaceuticals Inc. Annexon Biosciences Inc. iTeos Therapeutics S.A. Inozyme...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum” ). Poseida Therapeutics Inc. and iTeos Therapeutics S.A....
...TIGIT - T cell immunoreceptor with Ig and ITIM domains Elizabeth S. Eaton, Staff Writer Poseida Therapeutics Inc. iTeos Therapeutics S.A. Akouos...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...health systems at Alkermes plc (NASDAQ:ALKS). Robin Sawka, BioCentury Staff Constellation Pharmaceuticals Inc. Inspire Medical Systems Inc. Akcea Therapeutics Inc. iTeos Therapeutics S.A. Amplyx...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...after PD-1 that’s been validated with that kind of data,” said Joanne Lager, CMO of iTeos Therapeutics S.A....
BioCentury | Apr 1, 2020
Finance

Reversing course on IPO plans, iTeos draws $125M in private round with crossovers

...chemokine receptor 8 TIGIT - T cell immunoreceptor with Ig and ITIM domains Paul Bonanos, Associate Editor EOS100850 EOS884448 iTeos Therapeutics S.A. EOS-850 EOS-448...
BioCentury | Aug 13, 2019
Company News

Management tracks: Chouraqui leaving Novartis; plus iTeos, Immunovant, Biodesix

...is VP and head of the U.S. immunology, hepatology & dermatology franchise. Cancer immunotherapy company iTeos Therapeutics S.A....
...genomics and the Genetics Research Center of Excellence at AbbVie Inc. (NYSE:ABBV). Hongjiang Li, Staff Writer Biodesix Inc. iTeos Therapeutics S.A. Novartis...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...LLP, Merck Ventures, IP Group plc (LSE:IPO), AbbVie Ventures Products targeting DNA damage repair Cancer iTeos Therapeutics S.A....
BioCentury | Mar 26, 2019
Company News

Management tracks: Rubius, Abingworth, Arcus

...of an undisclosed new biotech company. The cancer company is seeking a successor. Immunotherapy company iTeos Therapeutics S.A....
...VP at 6 Dimensions Capital. BioCentury Staff Abingworth Aprea Therapeutics AB Arcus Biosciences Inc. CytomX Therapeutics Inc. Forma Therapeutics Inc. Intra-Cellular Therapies Inc. iTeos Therapeutics S.A. Lantheus...
BioCentury | Feb 22, 2019
Finance

MPM keeps building

...Therapeutics Inc. in December and led a $75 million series B round for immunotherapy play iTeos Therapeutics S.A....
Items per page:
1 - 10 of 26
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...Haul” ). Three of the four -- Annexon Inc. (NASDAQ:ANNX), Nurix Therapeutics Inc. (NASDAQ:NRIX) and iTeos Therapeutics...
...ENPP1 - Ectonucleotide pyrophosphatase/phosphodiesterase 1 Paul Bonanos, Associate Editor Annexon Inc. iTeos Therapeutics S.A. Nurix Therapeutics Inc. Inozyme Pharma Inc. 4D Molecular Therapeutics Inc. AlloVir iTeos Therapeutics...
BioCentury | Jul 21, 2020
Finance

As trio of companies enter IPO queue, four more propose terms

...Several more companies in the queue proposed terms for their listings, including Annexon Inc., iTeos Therapeutics...
...Inc. and Inozyme Pharma Inc. Paul Bonanos, Associate Editor Everest Medicines Ltd. Freeline Therapeutics Ltd. Checkmate Pharmaceuticals Inc. Annexon Biosciences Inc. iTeos Therapeutics S.A. Inozyme...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum” ). Poseida Therapeutics Inc. and iTeos Therapeutics S.A....
...TIGIT - T cell immunoreceptor with Ig and ITIM domains Elizabeth S. Eaton, Staff Writer Poseida Therapeutics Inc. iTeos Therapeutics S.A. Akouos...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...health systems at Alkermes plc (NASDAQ:ALKS). Robin Sawka, BioCentury Staff Constellation Pharmaceuticals Inc. Inspire Medical Systems Inc. Akcea Therapeutics Inc. iTeos Therapeutics S.A. Amplyx...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...after PD-1 that’s been validated with that kind of data,” said Joanne Lager, CMO of iTeos Therapeutics S.A....
BioCentury | Apr 1, 2020
Finance

Reversing course on IPO plans, iTeos draws $125M in private round with crossovers

...chemokine receptor 8 TIGIT - T cell immunoreceptor with Ig and ITIM domains Paul Bonanos, Associate Editor EOS100850 EOS884448 iTeos Therapeutics S.A. EOS-850 EOS-448...
BioCentury | Aug 13, 2019
Company News

Management tracks: Chouraqui leaving Novartis; plus iTeos, Immunovant, Biodesix

...is VP and head of the U.S. immunology, hepatology & dermatology franchise. Cancer immunotherapy company iTeos Therapeutics S.A....
...genomics and the Genetics Research Center of Excellence at AbbVie Inc. (NYSE:ABBV). Hongjiang Li, Staff Writer Biodesix Inc. iTeos Therapeutics S.A. Novartis...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...LLP, Merck Ventures, IP Group plc (LSE:IPO), AbbVie Ventures Products targeting DNA damage repair Cancer iTeos Therapeutics S.A....
BioCentury | Mar 26, 2019
Company News

Management tracks: Rubius, Abingworth, Arcus

...of an undisclosed new biotech company. The cancer company is seeking a successor. Immunotherapy company iTeos Therapeutics S.A....
...VP at 6 Dimensions Capital. BioCentury Staff Abingworth Aprea Therapeutics AB Arcus Biosciences Inc. CytomX Therapeutics Inc. Forma Therapeutics Inc. Intra-Cellular Therapies Inc. iTeos Therapeutics S.A. Lantheus...
BioCentury | Feb 22, 2019
Finance

MPM keeps building

...Therapeutics Inc. in December and led a $75 million series B round for immunotherapy play iTeos Therapeutics S.A....
Items per page:
1 - 10 of 26